Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 4
1953 1
1955 1
1956 1
1959 4
1960 1
1961 2
1964 3
1972 1
1973 14
1974 26
1975 37
1976 41
1977 49
1978 104
1979 215
1980 182
1981 281
1982 397
1983 445
1984 618
1985 817
1986 832
1987 837
1988 916
1989 1063
1990 1164
1991 1117
1992 1143
1993 1182
1994 1139
1995 1151
1996 1233
1997 1214
1998 1179
1999 1261
2000 1350
2001 1285
2002 1418
2003 1395
2004 1460
2005 1603
2006 1719
2007 1646
2008 1620
2009 1723
2010 1925
2011 2092
2012 2259
2013 2341
2014 2385
2015 2421
2016 2355
2017 2241
2018 2056
2019 1042
2020 22
Text availability
Article attribute
Article type
Publication date

Search Results

51,103 results
Results by year
Filters applied: . Clear all
Page 1
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
Zhang Y, et al. N Engl J Med 2019 - Clinical Trial. PMID 31150573
Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials. METHODS: In a parallel-group, multicenter, randomized, controlled, phase 3 trial, we compared gemcitabine and cisplatin as induction chemotherapy plus concurrent chemoradiotherapy with concurrent chemoradiotherapy alone. Patients with locoregionally advanced nasopharyngeal carcinoma were randomly assigned in a 1:1 ratio to receive gemcitabine (at a dose of 1 g per square meter of body-surface area on days 1 and 8) plus cisplatin (80 mg per square meter on day 1), administered every 3 weeks for three cycles, plus chemoradiotherapy (concurrent cisplatin at a dose of 100 mg per square meter every 3 weeks for three cycles plus intensity-modulated radiotherapy) or chemoradiotherapy alone. ...
Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials. METHODS: In a parallel-gr …
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE, et al. Lancet 2019 - Clinical Trial. PMID 30982686
METHODS: In this controlled, open-label, phase 2/3 trial, we randomly assigned 716 patients with histologically-confirmed advanced clinical stage cT2 or higher or nodal positive stage (cN+), or both, resectable tumours, with no evidence of distant metastases, via central interactive web-based-response system, to receive either three pre-operative and three postoperative 3-week cycles of 50 mg/m(2) epirubicin and 60 mg/m(2) cisplatin on day 1 plus either 200 mg/m(2) fluorouracil as continuous intravenous infusion or 1250 mg/m(2) capecitabine orally on days 1 to 21 (ECF/ECX; control group) or four preoperative and four postoperative 2-week cycles of 50 mg/m(2) docetaxel, 85 mg/m(2) oxaliplatin, 200 mg/m(2) leucovorin and 2600 mg/m(2) fluorouracil as 24-h infusion on day 1 (FLOT; experimental group). ...
METHODS: In this controlled, open-label, phase 2/3 trial, we randomly assigned 716 patients with histologically-confirmed advanced clinical …
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Shroff RT, et al. JAMA Oncol 2019 - Clinical Trial. PMID 30998813 Free PMC article.
INTERVENTIONS: Patients initially received gemcitabine, 1000 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel, 125 mg/m2, on days 1 and 8 of 21-day cycles. ...CONCLUSIONS AND RELEVANCE: Treatment with nab-paclitaxel plus gemcitabine-cisplatin prolonged median progression-free survival and overall survival vs those reported for historical controls treated with gemcitabine-cisplatin alone. ...
INTERVENTIONS: Patients initially received gemcitabine, 1000 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel, 125 mg/m2, on days 1 and …
Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity.
Volarevic V, et al. J Biomed Sci 2019 - Review. PMID 30866950 Free PMC article.
BACKGROUND: Cisplatin (cis-diamminedichloroplatinum II, CDDP) is one of the most effective chemotherapeutic agents. However, its clinical use is limited due to the severe side effects, including nephrotoxicity and acute kidney injury (AKI) which develop due to renal accumulation and biotransformation of CDDP. ...
BACKGROUND: Cisplatin (cis-diamminedichloroplatinum II, CDDP) is one of the most effective chemotherapeutic agents. However, its clin …
Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury.
Holditch SJ, et al. Int J Mol Sci 2019 - Review. PMID 31226747 Free PMC article.
Cisplatin is a widely used chemotherapeutic agent used to treat solid tumours, such as ovarian, head and neck, and testicular germ cell. A known complication of cisplatin administration is acute kidney injury (AKI). The development of effective tumour interventions with reduced nephrotoxicity relies heavily on understanding the molecular pathophysiology of cisplatin-induced AKI. ...
Cisplatin is a widely used chemotherapeutic agent used to treat solid tumours, such as ovarian, head and neck, and testicular germ ce
Cisplatin-Induced Ototoxicity in Rats Is Driven by RIP3-Dependent Necroptosis.
Choi MJ, et al. Cells 2019. PMID 31052605 Free PMC article.
Cisplatin-induced early-onset ototoxicity is linked to hearing loss. The mechanism by which cisplatin causes ototoxicity remains unclear. ...The treatment of Nec-1, a selective RIP1 inhibitor, resulted in markedly suppression of cisplatin-induced cell death in HEI-OC1 cells, whereas Z-VAD treatment did not change the cisplatin-induced cell death. ...
Cisplatin-induced early-onset ototoxicity is linked to hearing loss. The mechanism by which cisplatin causes ototoxicity remai
Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression.
Huang X, et al. Mol Cancer 2019. PMID 30927924 Free PMC article.
BACKGROUND: Cisplatin (CDDP) treatment is one of the most predominant chemotherapeutic strategies for patients with gastric cancer (GC). ...
BACKGROUND: Cisplatin (CDDP) treatment is one of the most predominant chemotherapeutic strategies for patients with gastric cancer (G …
Inhaled Cisplatin for NSCLC: Facts and Results.
Kosmidis C, et al. Int J Mol Sci 2019 - Review. PMID 31022839 Free PMC article.
In the current review, we will focus on the administration of inhaled cisplatin based on published data....
In the current review, we will focus on the administration of inhaled cisplatin based on published data....
Has vitamin E any shreds of evidence in cisplatin-induced toxicity.
Hakiminia B, et al. J Biochem Mol Toxicol 2019 - Review. PMID 31115123
The evidence is growing over the protective effects of antioxidants on cisplatin-induced adverse reactions especially nephrotoxicity. ...Although the data from most of the studies are in favors of protective effects of vitamin E against cisplatin-induced toxicity, more clinical trials are needed to clarify the clinical importance of vitamin E administration as an antioxidant during cisplatin therapy in cancer condition....
The evidence is growing over the protective effects of antioxidants on cisplatin-induced adverse reactions especially nephrotoxicity. …
Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H, et al. JAMA Oncol 2019 - Clinical Trial. PMID 30896757 Free PMC article.
The number of patients who did not complete 6 cycles was 53 (20.1%) for the doxorubicin plus cisplatin group, 45 (17.1%) for the docetaxel plus cisplatin group, and 63 (24.0%) for the paclitaxel plus carboplatin group. ...After a median follow-up period of 7 years, there was no statistical difference of progression-free survival (doxorubicin plus cisplatin, 191; docetaxel plus cisplatin, 208; paclitaxel plus carboplatin, 187; P = .12) or overall survival (doxorubicin plus cisplatin, 217; docetaxel plus cisplatin, 223; paclitaxel plus carboplatin, 215; P = .67) among the 3 groups. ...
The number of patients who did not complete 6 cycles was 53 (20.1%) for the doxorubicin plus cisplatin group, 45 (17.1%) for the doce …
51,103 results
Jump to page
Feedback